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ㅋ
The symptoms related to gastrointestinal (GI) tract are sometimes chief complaints in patients with endocrine disease. Thyro-
toxicosis is a rare, but notable cause for unexplained and repeated vomiting. Here, we report an adolescent patient with thyro-
toxicosis who was initially presented with repeated vomiting and epigastric pain. A 13-year-old female was referred to a GI 
outpatient department for evaluation of vomiting and abdominal pain from a pediatric clinic. Esophagogastroduodenoscopy 
revealed acute gastritis with duodenogastric reflux and suspicious reflux esophagitis of minimal change, but there was no sig-
nificant improvement after treatment and as a result she was admitted to the emergency room. She was subsequently diag-
nosed as Graves’ disease because an initial laboratory test at the GI outpatient department revealed thyroid stimulating hor-
mone ＜ 0.01 μIU/mL and additional blood tests showed elevated thyroid hormones and positive thyroid stimulating hormone 
receptor antibody. The vomiting and epigastric pain improved remarkably after treatment with antithyroid drugs. Clinicians 
should consider the possibility of thyrotoxicosis in patient with unexplained and repeated vomiting.
(J Neurogastroenterol Motil 2010;16:428-432)
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Introduction
Vomiting is one of the most common symptoms in gastro-
enterology clinics and usually originates from gastrointestinal 
(GI) disorders. However, various extraintestinal disorders can al-
so cause vomiting.
1,2
Patients with thyroid disorders may present with a wide 
range of GI symptoms (eg, diarrhea, frequent defecation, con-
stipation, dyspepsia, nausea, vomiting and abdominal pain).
3 
Some patients with masked thyrotoxicosis who lack the unique 
clinical feature usually presented as cardiovascular abnormalities 
such as heart failure, but also occasionally as GI abnormalities in-
cluding dysphagia,
4 vomiting
5 and abdominal pain.
6 We report a 
case of an adolescent female with undiagnosed thyrotoxicosis who 
was initially treated for vomiting under a diagnosis of duodeno-
gastric reflux and reflux esophagitis.
Case Report
A 13-year-old female patient was referred to the GI out-
patient department of our hospital from a pediatric clinic to un-Thyrotoxic Vomiting
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Figure 1. Endoscopic findings show mild erythema with whitish turbidity around Z-line (A) and large amount of bile-mixed fluid in the gastric 
lumen with bile stainings on the gastric mucosa (B). After suctioning of all fluid and washing the gastric mucosa with water, multiple linear mild 
erythematous changes on gastric mucosa are observed (C, D).
dergo the esophagogastroduodenoscopy for the evaluation of re-
current vomiting that lasted for 8 days. The vomiting usually oc-
curred in the afternoon and was bilious in nature. Although vom-
iting was not related to food intake, she had avoided eating be-
cause of recurrent vomiting. She also complained of nausea, bor-
ing epigastric pain and palpitation, but denied diarrhea or me-
lena. She had lost 8 kg of weight over 4 months, and her weight 
was 39.4 kg (10-25 percentile) and height was 156 cm (50-75 
percentile) at presentation. Past history and family history were 
not remarkable. She was in Tanner stage 4. Menarche occurred 6 
months ago, and menstrual cycles were irregular. Physical exami-
nation revealed a dehydrated tongue, cachexic and anxious ap-
pearance. Her blood pressure was 100/80 mmHg, pulse rate was 
110/min, respiratory rate was 20/min and body temperature was 
36.6
oC. There was no definite enlargement or palpable mass on 
the anterior neck, eye abnormality or lymphadenopathy. The ab-
domen was soft with normal bowel sound and there was no direct 
or rebound tenderness on the abdomen. Electrocardiography show-
ed sinus tachycardia. Plain abdominal X-ray showed nonspecific 
findings. Because she had weight loss and palpitation with anxi-
ety, thyroid stimulating hormone (TSH) was included in the ini-
tial laboratory test. Esophagogastroduodenoscopy at the first visit 
of GI outpatient department revealed mild mucosal erythema on 
Z-line and acute erythematous gastritis with large amount of duo-
denogastric reflux (Fig. 1). Helicobacter pylori rapid urease test 
was negative. She was prescribed a proton pump inhibitor, proki-
netic and mucosal coating agent (sucralfate) on the basis of her 
endoscopic diagnosis with GI department follow up after 2 weeks. 
Her vomiting improved during the first 2 days after medication, 
however, she visited the emergency department (ED) 5 days later Soyeon Shim, et al
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Figure 2. Ultrasonography of the thyroid glands. Both lobes in the 
transverse plane reveal diffusely enlarged round lobes and decreased 
parenchymal echogenecity (A). Doppler examination for right lobe (B) 
and left lobe (C) demonstrates increased vascularity.
because of recurred vomiting and boring epigastric pain. Her 
blood pressure was 140/80 mmHg, pulse rate was 88/min, respi-
ratory rate was 20/min and body temperature was 36.8
oC. Physi-
cal examination revealed mild epigastric direct tenderness. The 
physician of the ED found that she already had blood tests in-
cluding TSH at GI outpatient department and it revealed TSH
＜ 0.01 μIU/mL (normal range 0.35-5.55 μIU/mL). Complete 
blood count with differential, electrolyte and glucose were within 
normal limit. A liver function tests showed albumin 4.34 g/dL 
(normal range 3.8-5.3 g/dL), total bilirubin 2.47 mg/dL (normal 
range 0.3-1.2 mg/dL), alkaline phosphatase 139 IU/L (normal 
range 25-100 IU/L), AST 30 IU/L (normal range 0-35 IU/L) 
and ALT 38 IU/L (normal range 0-35 IU/L). A repeated liver 
function test at ED showed total bilirubin 1.7 mg/dL, alkaline 
phosphatase 133 IU/L, AST 30 IU/L, ALT 42 IU/L and mag-
nesium and calcium were within normal limit. Subsequent blood 
tests for the thyroid showed free triiodothyroxine (T3) ＞ 8.0 ng/ 
mL (normal range 0.60-1.81 ng/mL), free thyroxine (T4) ＞ 12.0 
ng/dL (normal range 0.89-1.76 ng/dL), TSH receptor antibody 
37.4% (normal range ≤ 15.0%), anti-thyroid microsomal anti-
body 6.22 U/mL (normal range ≤ 3.0 U/mL) and thyroglobu-
lin antibody 6.91 U/mL (normal range ≤ 3.0 U/mL). Thyroid 
ultrasonography revealed diffusely enlarged glands, decreased 
parenchymal echogenecity and increased vascularity of both glands 
(Fig. 2). Treatment was initiated with propylthiouracil (PTU) 
3.75mg/kg/day and propranolol 1 mg/kg/day, after 4 days of treat-
ment, vomiting, epigastric pain and palpitation were improved 
remarkably. She was discharged with a maintenance dose of PTU 
(3.75 mg/kg/day) without prokinetic or proton pump inhibitor.
She was hospitalized again 5 days later because vomiting had 
recurred. Liver function tests returned to normal limits, but thy-
roid function tests were still elevated (TSH ＜ 0.01 μIU/mL, 
free T3 6.31 ng/mL and free T4 5.09 ng/dL). We switched 
treatment from PTU to methimazole 0.4 mg/kg/day and added 
inorganic iodine (Lugol’s solution) for 5 days to prevent thyroid 
hormone release. After 3 days, there was no further vomiting, and 
free T3 and free T4 were decreased to 4.46 ng/mL and 2.24 
ng/dL, respectively. She was discharged with a maintenance dose Thyrotoxic Vomiting
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of methimazole (0.4 mg/kg/day) and propranolol (1 mg/kg/day).
After 2 months with methimazole and propranolol main-
tenance therapy, her symptoms were stable and free T4 returned 
to normal limits (1.27 ng/dL) despite still having low level of 
TSH (＜ 0.01 μIU/mL). Over next 16 months with methima-
zole monotherapy, vomiting has not recurred and she became eu-
thyroid with normalized TSH receptor antibody.
Discussion
GI symptoms such as hyperphagia, diarrhea, and frequent 
defecation are commonly associated with thyrotoxicosis, whereas 
vomiting, abdominal pain, and dysphagia are uncommon. Al-
though vomiting, nausea and abdominal pain have not been gen-
erally included as common presenting symptoms for thyrotox-
icosis, a review of 25 newly diagnosed thyrotoxicosis cases re-
ported that the significant number of thyrotoxic patients com-
plained of vomiting (44%), nausea (28%) and abdominal pain 
(20%).
7 One or more of these abdominal symptoms were in-
cluded as a chief complaint in 36% of cases reviewed.
7
Interestingly, thyrotoxic vomiting can occur intermittently, 
and unique clinical features of thyrotoxicosis including goiter, 
ophthalmopathy such as exophthalmos or lid retraction are rarely 
associated with cases of thyrotoxic vomiting.
5,6,8 Our patient was 
diagnosed as hyperthyroidism caused by Graves’ disease based on 
autoantibodies and sonographic finding. She was 13-year-old 
child and the characteristics of pediatric Graves’ disease also 
make clinician difficult to diagnose thyrotoxicosis. In pediatric 
Graves’ disease, the size of the thyroid gland is highly variable 
and the goiter may go unnoticed in patients with a slightly en-
larged thyroid gland, and ophthalmic abnormalities are less se-
vere in children than in adults.
9 Therefore, children with un-
diagnosed thyrotoxicosis may initially be referred to cardiologists 
with a heart murmur, gastroenterologists with GI symptoms and 
failure to thrive, or psychiatrist because of challenging behavior 
and school refusal before being referred to an endocrinologist.
10
When rare GI symptoms like vomiting present as initial sy-
mptoms in patients with thyrotoxicosis and there are no typical 
features of thyrotoxicosis, it can be misdiagnosed as GI disorders. 
If the physician is misled to another GI disorder and vomiting is 
prolonged for several weeks under wrong treatment, this patient 
not only can progress to a life-threatening situation, but also may 
have many unnecessary tests under suspicion of functional vomit-
ing or even exploratory laparotomy.
1,6,11
In cases of thyrotoxicosis that showed only GI symptoms, di-
agnostic clues might be chronicity of symptoms, prominent 
weight loss and tachycardia.
6,8,12 In our patient, the prominent 
weight loss over several months, palpitation and anxiety were 
clues to the suspicion of thyrotoxicosis. However, since these 
symptoms are not pathognomic signs of thyrotoxicosis and often 
accompanied by other GI symptoms, proper diagnosis is difficult 
and delayed considerably.
There are several possible mechanisms by which thyrotoxic 
vomiting develops. The first proposed mechanism is an increase 
in β-adrenergic activity due to an increased number of β-adre-
nergic receptors.
13 There have been several reports of rapid sy-
mptomatic improvement after administration of β-blockers be-
fore the normalization of thyroid hormones.
6,8,12 Based on these 
reports, it is conceivable that the vomiting in thyrotoxicosis may 
be attributed to sympathomimetic effects of thyroid hormones as 
dysrhythmias, fever, tremors, palpitations and anxiety. The rapid 
symptomatic improvement may reflect the ability of β-blockers to 
reduce the peripheral conversion of thyroxine to triiodothyro-
nine.
12
Second, increased thyroid hormones can cause emesis. There 
is a reported case that symptoms were not improved by the ad-
ministration of β-blockers but improved after thyroid hormone 
levels normalized.
14 In our case, clinical symptoms were tempora-
rily improved by the administration of β-blocker with subsequent 
recurrence within 5 days and were completely improved after thy-
roid hormone levels decreased to near normal range by Lugol’s 
solution. The mechanism for vomiting in thyrotoxicosis may be 
similar to that for vomiting in hyperemesis gravidarum. In-
creased α-subunit of human chorionic gonadotropin induces se-
cretion of thyroxine through a TSH-like activity.
15 However, it is 
still controversial whether thyroid hormones themselves act as an 
emetic factor in thyrotoxic vomiting, although it has been specu-
lated that thyroid hormones stimulate the chemical trigger zone.
5
Third, thyroid hormones can alter gastric motility and de-
crease gastric emptying secondary to the malfunction of the py-
loric sphincter. A plausible explanation for this phenomenon is 
that thyroid hormones alter magnesium homeostasis, and hypo-
magnesemia affect smooth muscle directly or autonomic in-
nervations of the upper GI smooth muscle.
16,17 The rate of gastric 
emptying is slightly increased after the restoration of euthyroid-
ism
18 and postprandial tachygastrias are significantly reduced af-
ter antithyroid therapy.
19,20
Fourth, the estrogen was suggested an emetic cause in thyro-
toxicosis because there are female predominance in thyrotoxic 
vomiting and estrogen level could be increased in patients of both Soyeon Shim, et al
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sexes with thyrotoxicosis.
5,21 And then the raised estrogen level 
may induce nausea and vomiting only in susceptible patients.
22
Lastly, it was suggested that functional duodenal obstruction 
in thyrotoxicosis may present much like the obstruction in superi-
or mesenteric artery syndrome.
14 Possible causes of this obstruc-
tion are prominent weight loss, supine position in a patient with 
prolonged and severe illness and hypermotility induced volvulus 
of duodenal third portion.
Thyrotoxic vomiting has a excellent prognosis and usually 
improved within several days after initiation of antithyroid treat-
ment in the majority of reported cases.
5-8,12 However, since our 
patient was pediatric Graves’ disease, we should consider genetic 
background of Graves’ disease and higher frequency of relapse 
than adult.
9
In conclusion, the possibility of atypical thyrotoxicosis should 
be considered in patients with persistent unexplained vomiting. 
Since symptomatic improvement is related to the thyroid hor-
mone level, appropriate treatment strategies and meticulous sur-
veillance for the thyroid hormone level are mandatory.
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